Mind Medicine (MindMed) I... (MNMD)
| Bid | 6.4 |
| Market Cap | 498.56M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -108.68M |
| EPS (ttm) | -1.54 |
| PE Ratio (ttm) | -4.3 |
| Forward PE | -3.83 |
| Analyst | Buy |
| Ask | 6.61 |
| Volume | 604,137 |
| Avg. Volume (20D) | 1,908,427 |
| Open | 6.39 |
| Previous Close | 6.39 |
| Day's Range | 6.28 - 6.64 |
| 52-Week Range | 4.70 - 10.44 |
| Beta | 2.39 |
About MNMD
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has com...
Analyst Forecast
According to 9 analyst ratings, the average rating for MNMD stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 202.34% from the latest price.
Stock Forecasts
1 month ago · seekingalpha.com
Mind Medicine (MindMed) Inc. (MNMD) Q4 2024 Earnings Call TranscriptMind Medicine (MindMed) Inc. (NASDAQ:MNMD ) Q4 2024 Earnings Conference Call March 6, 2025 8:00 AM ET Company Participants Stephanie Fagan - Chief Corporate Affairs Officer Rob Barrow - CEO Dan Karlin...
